Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas Blood, Mar 2013; 121: 2563 - 2566.
[anti-HA]
Regulation of the PI3-K/Akt Survival Pathway in the Rat Endometrium Biol Reprod, Mar 2013; 88: 79.
[Akt3]
RNA elements directing in vivo assembly of the 7SK/MePCE/Larp7 transcriptional regulatory snRNP Nucleic Acids Res., Mar 2013; 10.1093/nar/gkt159.
[LA]
Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements Haematologica, Mar 2013; 98: 404 - 408.
[JAK2]
A synthetic peptide corresponding to residues in human Annexin V was used as an immunogen.
Buffer
Store at -20C. Buffer: 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA. Stable for 12 months from date of receipt.
Annexin V (ANV) is a calcium-dependent glycoprotein with a potent anticoagulant capacity in vitro, mainly as a result of its negatively charged membrane phospholipids, and capable of inhibiting the prothrombinase and Tensa complexes to reduce plaque adhesion and aggregation. Circulating ANV can be released from the cells of the vascular wall (endothelial cells, smooth muscles cells) or from secretor cells of the spleen and liver. Once it is in the plasma, it binds to blood cells (platelets and erythrocytes) or to endothelial cells (1). Annexin V is also a Ca(2+) dependent membrane-binding protein protein that forms voltage-dependent Ca2+ channels in phospholipid bilayers (2). Structural features suggest that Annexin V attaches with its convex face to membrane by specific calcium mediated interactions with at least three phospholipids. The adjacent membrane bilayer may thus become locally disordered and permeable to allow calcium inflow through the central polar channel of the molecule.
Related Pathway
* Shipping is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
